Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03332173 | Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM) | completed | Phase 2 | 44 | BeiGeneINDUSTRY | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03493451 | Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms | completed | Phase 2 | 77 | BeiGeneINDUSTRY | 5 | Oct 26, 2024 | clinicaltrials |
| NCT03520920 |
| BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) |
| completed |
| Phase 2 |
| 41 |
| BeiGeneINDUSTRY |
| 1 |
| Oct 26, 2024 |
| clinicaltrials |
| NCT03846427 | Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma(MAGNOLIA) | completed | Phase 2 | 68 | BeiGeneINDUSTRY | 9 | Oct 26, 2024 | clinicaltrials |
| NCT03955783 | Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies | completed | Phase 1 | 78 | Sanjay MohanOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT00285259 | Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) | completed | Phase 2 | 112 | Astellas Pharma IncINDUSTRY | 1 | Oct 21, 2024 | clinicaltrials |
| NCT03340766 | Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)(HARBOUR) | completed | Phase 1 | 31 | AmgenINDUSTRY | 6 | Oct 17, 2024 | clinicaltrials |
| NCT02927964 | TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma | completed | Phase 1 / Phase 2 | 21 | Robert LowskyOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT04134936 | Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL | completed | Phase 1 | 66 | MorphoSys AGINDUSTRY | 9 | Oct 16, 2024 | clinicaltrials |
| NCT02692248 | Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT | completed | Phase 2 | 64 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT03989466 | Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia | completed | Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT03595800 | Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen(HaploMUD-RIC) | completed | Phase 3 | 9 | Institut Paoli-CalmettesOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT00747123 | A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma | completed | Phase 2 | 30 | CelgeneINDUSTRY | 1 | Oct 3, 2024 | clinicaltrials |
| NCT02294487 | Study of the Immune Response After Vaccination in Multiple Myeloma Patients | completed | — | 19 | Wake Forest University Health SciencesOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT02375555 | Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM | completed | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04798586 | MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma | completed | Phase 1 | 4 | PfizerINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT02939183 | Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma(INTREPID-1) | completed | Phase 1 | 61 | AmgenINDUSTRY | 4 | Sep 26, 2024 | clinicaltrials |
| NCT03788291 | Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma | completed | Phase 2 | 39 | University of RochesterOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT02532257 | Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma | completed | Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT02892383 | Quality of Life the Danish Multiple Myeloma Patients(QoL-MM) | completed | — | 681 | Odense University HospitalOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT01460914 | Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment | completed | — | 34 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT01724346 | Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 3 | 269 | Pharmacyclics LLC.INDUSTRY | 16 | Sep 19, 2024 | clinicaltrials |
| NCT01827137 | WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 20 | Sellas Life Sciences GroupINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02633059 | Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 33 | Mayo ClinicOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02953652 | Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | completed | Phase 2 | 55 | HUYABIO International, LLC.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT04038359 | A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma(TEMPO) | completed | Phase 2 | 103 | SecuraBioINDUSTRY | 8 | Sep 19, 2024 | clinicaltrials |
| NCT04500587 | Phase 1 First in Human Study of ZN-d5 as a Single Agent | completed | Phase 1 | 39 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.INDUSTRY | 7 | Sep 19, 2024 | clinicaltrials |
| NCT05199337 | Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis | completed | Phase 1 / Phase 2 | 18 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.INDUSTRY | 7 | Sep 19, 2024 | clinicaltrials |
| NCT03078855 | A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma(ILyAD) | completed | Phase 3 | 211 | Jonathan FriedbergOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT03267888 | Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | Emory UniversityOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT02633137 | Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma | completed | Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT02953301 | Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)(RESMAIN) | completed | Phase 2 | 201 | 4SC AGINDUSTRY | 12 | Aug 30, 2024 | clinicaltrials |
| NCT04274738 | A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 | completed | Phase 1 | 16 | X4 PharmaceuticalsINDUSTRY | 2 | Aug 27, 2024 | clinicaltrials |
| NCT04847050 | A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2024 | clinicaltrials |
| NCT01793233 | Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas | completed | — | 203 | Children's Oncology GroupNETWORK | 2 | Aug 26, 2024 | clinicaltrials |
| NCT06160167 | Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs | completed | — | 4,204 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT00991211 | Bendamustine Plus Rituximab Versus CHOP Plus Rituximab | completed | Phase 3 | 549 | University of GiessenOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT01456351 | Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab | completed | Phase 3 | 230 | University of GiessenOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT02157181 | Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab | completed | Phase 2 | 89 | Jurgen BarthOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03829020 | Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 9 | Mayo ClinicOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03110562 | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma(BOSTON) | completed | Phase 3 | 402 | Karyopharm Therapeutics IncINDUSTRY | 21 | Aug 21, 2024 | clinicaltrials |
| NCT04450069 | CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies | completed | Phase 1 | 18 | Calibr, a division of Scripps ResearchOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT04760405 | The TOTOM Trial: Tai Chi to Optimize Transplant Outcomes for Multiple Myeloma | completed | N/A | 12 | University of ArizonaOTHER | 1 | Aug 16, 2024 | clinicaltrials |
| NCT00487305 | Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma | completed | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06552221 | Finistere Myeloma Observatory (OMYFIN)(OMYFIN) | completed | — | 300 | University Hospital, BrestOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06549361 | A Retrospective Study on Extranodal DLBCL | completed | — | 5,023 | Ruijin HospitalOTHER | 1 | Aug 12, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Oct 26, 2024source: clinicaltrials